Canada’s Biosimilar Revolution Continues

Delving deeper into the promising landscape shaped by Ontario’s innovative biosimilar regulations. Discover how these policies are fostering enhanced accessibility for patients and driving positive transformations in the pharmaceutical industry.   There are a few similarities and a few differences between biosimilars and generic drugs. A generic drug is an exact copy of its reference …

Canada’s Biosimilar Revolution Continues Read More »